Clinical Trials Sponsored by OPKO IP Holdings II, Inc.

Total 5 results

OPKO IP Holdings II, Inc.

Completed

Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency

Vitamin D Deficiency | Chronic Kidney Disease | Hyperparathyroidism, Secondary

United States
OPKO IP Holdings II, Inc.

Completed

Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease Subjects

Chronic Kidney Disease | Secondary Hyperparathyroidism | Chronic Renal Failure | Chronic Renal Insufficiency

United States
OPKO IP Holdings II, Inc.

Completed

Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT)

Chronic Kidney Disease | Secondary Hyperparathyroidism | Chronic Renal Failure | Chronic Renal Insufficiency

United States
OPKO IP Holdings II, Inc.

Completed

Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency

Vitamin D Deficiency | Chronic Kidney Disease | Hyperparathyroidism, Secondary

United States
OPKO IP Holdings II, Inc.

Completed

Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease

Chronic Kidney Disease | Secondary Hyperparathyroidism | Chronic Renal Failure | Chronic Renal Insufficiency

Canada, United States

3

Subscribe